ImmuPharma publishes findings into $30bn peptide therapeutics market
‘Nature Communications,’ a peer reviewed research journal published a revelatory piece yesterday on the proprietary technology Urelix™ from Ureka, a subsidiary of .
The publication was entitled: "Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo" and was written by, among others, Dr. Robert Zimmer, ImmuPharma's Chief Scientific Officer, and Dr Sébastien R. Goudreau, Head of Research at Ureka.
Ureka is currently conducting research into new, original peptide molecules that could launch drug candidates for a whole range of diseases. The article describes, for the first time, “the unique properties of oligourea foldamers” as vehicles for improving the pharmaceutical properties of peptides.
Peptides, the article argues, have gained wide-ranging attention in the last decade and have now become part of the main strategies for developing new medicines.
However, despite this substantial progress, “successful development of peptides as drugs still requires a number of limitations to be addressed, including short in vivo half-lives and poor membrane permeability.”
The study has honed in on areas such as the treatment of Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis) as proof of concept for Ureka’s technology.
Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, commented: "Natural peptides play key roles in human biological processes and are effective and selective signaling molecules that bind to specific receptors on cells. Using natural peptides as drugs is not so effective because they are quickly broken down.
To put it simply, our technology overcomes these challenges and represents an intelligent way to design novel drugs. The global peptide therapeutics market achieved sales of $30 billion in 2018."
For more news and updates on ImmuPharma:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.